Main Article Content


The drug delivery technology landscape has become highly competitive and rapidly evolving. More and more developments in delivery systems are being integrated to optimize the efficacy and cost-effectiveness of the therapy. Peptides, proteins and DNA-based therapeutics cannot be effectively delivered by conventional means. To control the delivery rate of active agents to a predetermined site in human body has been one of the biggest challenges faced by drug industry. Controlled release  of  drugs  onto  the  epidermis  with assurance  that  the  drug  remains  primarily  localized  and  does  not enter  the  systemic  circulation in significant  amounts is an area  of  research  that is successively  done  by  the  microsponge  delivery  system. The Microsponge Delivery System (MDS) is a unique technology for the controlled release of topical agents and consists of macroporous beads, typically 10-25 microns in diameter, loaded with active agent. When applied to the skin, the microsponge releases its active ingredient on a time mode and also in response to other stimuli (rubbing, temperature, pH, etc). Microsponge technology offers entrapment of ingredients and is believed to contribute towards reduced side effects, improved stability, increased elegance, and enhanced formulation flexibility. In addition, numerous studies have confirmed that microsponge systems are non-irritating, non-mutagenic, non-allergenic, and non-toxic. MDS technology is being used currently in cosmetics, over-the-counter (OTC) skin care, sunscreens and prescription products.


Microsponge transdermal delivery proteins and peptides

Article Details

How to Cite
Viral Shaha, Hitesh Jain, Jethva Krishna, & Pramit Patel. (2010). Microsponge drug delivery: A Review. International Journal of Research in Pharmaceutical Sciences, 1(2). Retrieved from